GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-10.89
Forward P/E Ratio-10.19
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$1.78 per share
Price / Book10.71
EPS (Most Recent Fiscal Year)($1.75)
Return on Equity-127.89%
Return on Assets-100.59%
GTX (NASDAQ:GTXI) Frequently Asked Questions
What is GTX's stock symbol?
GTX trades on the NASDAQ under the ticker symbol "GTXI."
How were GTX's earnings last quarter?
GTx, Inc. (NASDAQ:GTXI) released its earnings results on Tuesday, May, 15th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.19. View GTX's Earnings History.
When is GTX's next earnings date?
What price target have analysts set for GTXI?
2 brokerages have issued twelve-month target prices for GTX's shares. Their predictions range from $30.00 to $45.00. On average, they expect GTX's share price to reach $37.50 in the next twelve months. View Analyst Ratings for GTX.
Who are some of GTX's key competitors?
Some companies that are related to GTX include Myokardia (MYOK), Mallinckrodt (MNK), Biohaven Pharmaceutical (BHVN), Zogenix (ZGNX), TherapeuticsMD (TXMD), Cambrex (CBM), Pacira Pharmaceuticals (PCRX), G1 Therapeutics (GTHX), ARMO Biosciences (ARMO), Innoviva (INVA), Wave Life Sciences (WVE), Myovant Sciences (MYOV), Amneal Pharmaceuticals (AMRX), Mirati Therapeutics (MRTX) and Radius Health (RDUS).
Who are GTX's key executives?
GTX's management team includes the folowing people:
- Dr. Robert James Wills, Exec. Chairman (Age 64)
- Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
- Mr. Henry P. Doggrell, VP, Chief Legal Officer, Gen. Counsel & Sec. (Age 69)
- Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
- Dr. Diane C. Young M.D., Chief Medical Officer and VP (Age 61)
Has GTX been receiving favorable news coverage?
Press coverage about GTXI stock has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. GTX earned a coverage optimism score of 0.01 on Accern's scale. They also gave news coverage about the biopharmaceutical company an impact score of 44.86 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are GTX's major shareholders?
GTX's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BVF Inc. IL (2.79%), Rock Springs Capital Management LP (1.62%), Millennium Management LLC (0.56%), Point72 Asset Management L.P. (0.49%), Federated Investors Inc. PA (0.40%) and Caxton Corp (0.23%). Company insiders that own GTX stock include Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Peak Foundation Pyramid. View Institutional Ownership Trends for GTX.
Which major investors are selling GTX stock?
GTXI stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL and Caxton Corp. Company insiders that have sold GTX company stock in the last year include Henry Patton Doggrell, Jason T Shackelford and Marc Steven Hanover. View Insider Buying and Selling for GTX.
Which major investors are buying GTX stock?
GTXI stock was purchased by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Point72 Asset Management L.P., Federated Investors Inc. PA, Millennium Management LLC, Element Capital Management LLC, GSA Capital Partners LLP and Northern Trust Corp. View Insider Buying and Selling for GTX.
How do I buy shares of GTX?
Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GTX's stock price today?
One share of GTXI stock can currently be purchased for approximately $19.06.
How big of a company is GTX?
GTX has a market capitalization of $435.95 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.
How can I contact GTX?
GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]
MarketBeat Community Rating for GTX (GTXI)MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.